10.29.19

Eyenovia Advances MicroLine for the Treatment of Presbyopia; Reprioritizes Late-Stage Ophthalmology Pipeline

Source: Eyenovia

06.05.19

Eyenovia Enrolls First Patient in Phase 3 CHAPERONE Study for Progressive Myopia

Source: Eyenovia

05.06.19

Eyenovia Announces Presentation of Successful Phase 3 Studies at the ASCRS

Source: Eyenovia

02.25.19

Eyenovia Announces Confirmatory Results from Second MicroStat Phase 3 Registration Study for Mydriasis

Source: Eyenovia

02.13.19

Eyenovia Confirms Expanded MicroProst Phase 3 Indication to Enroll Broad Patient Population for IOP Lowering

Source: Eyenovia

02.06.19

Eyenovia Announces FDA Acceptance of IND Application for MicroPine

Source: Eyenovia

01.30.19

Eyenovia Announces Positive Results in the MicroStat MIST-1 Phase 3 Registration Study for Mydriasis

Source: Eyenovia

12.04.18

Eyenovia Completes Patient Enrollment in MicroStat MIST-1 Study and Enrolls First Patient in MIST-2 Study

Source: Eyenovia

11.28.18

Eyenovia Publishes PG21 Phase 2 Trial Results Examining IOP Lowering Effect and Patient Usability

Source: Eyenovia

11.26.18

Eyenovia Initiates Phase 3 MicroStat Program for Pharmacologic Mydriasis: Enrolls First Patient in MIST-1 Study

Source: Eyenovia

View more stories